[go: up one dir, main page]

NO882341D0 - Ekspresjon av humant proapolipoprotein a-i. - Google Patents

Ekspresjon av humant proapolipoprotein a-i.

Info

Publication number
NO882341D0
NO882341D0 NO882341A NO882341A NO882341D0 NO 882341 D0 NO882341 D0 NO 882341D0 NO 882341 A NO882341 A NO 882341A NO 882341 A NO882341 A NO 882341A NO 882341 D0 NO882341 D0 NO 882341D0
Authority
NO
Norway
Prior art keywords
proapolipoprotein
sequence
expression
expression vectors
humant
Prior art date
Application number
NO882341A
Other languages
English (en)
Other versions
NO179253B (no
NO882341L (no
NO179253C (no
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO882341D0 publication Critical patent/NO882341D0/no
Publication of NO882341L publication Critical patent/NO882341L/no
Publication of NO179253B publication Critical patent/NO179253B/no
Publication of NO179253C publication Critical patent/NO179253C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
NO882341A 1987-05-28 1988-05-27 Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet NO179253C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (4)

Publication Number Publication Date
NO882341D0 true NO882341D0 (no) 1988-05-27
NO882341L NO882341L (no) 1988-11-29
NO179253B NO179253B (no) 1996-05-28
NO179253C NO179253C (no) 1996-09-04

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882341A NO179253C (no) 1987-05-28 1988-05-27 Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet

Country Status (33)

Country Link
US (1) US5059528A (no)
EP (1) EP0293357B1 (no)
JP (1) JP2634193B2 (no)
KR (1) KR970000808B1 (no)
CN (1) CN1031892C (no)
AT (1) ATE89006T1 (no)
AU (1) AU615654B2 (no)
CA (1) CA1323851C (no)
CY (1) CY1809A (no)
CZ (1) CZ283648B6 (no)
DD (1) DD291093A5 (no)
DE (1) DE3880739T2 (no)
DK (1) DK175686B1 (no)
EG (1) EG19101A (no)
ES (1) ES2054878T3 (no)
FI (1) FI100056B (no)
GB (1) GB8712540D0 (no)
HK (1) HK137794A (no)
HU (1) HU204562B (no)
IE (1) IE62422B1 (no)
IL (1) IL86480A (no)
LT (1) LT3600B (no)
LV (1) LV5288A3 (no)
NO (1) NO179253C (no)
NZ (1) NZ224808A (no)
PL (1) PL158064B1 (no)
PT (1) PT87562B (no)
RU (1) RU2009198C1 (no)
SG (1) SG131594G (no)
SK (1) SK363888A3 (no)
SU (1) SU1834904A3 (no)
UA (1) UA19765A (no)
ZA (1) ZA883824B (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
IE914102A1 (en) * 1990-11-26 1992-06-03 Genetics Inst Expression of pace in host cells and methods of use thereof
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
EP0559795B1 (en) * 1990-11-30 1995-12-27 Monoclonetics International, Inc. Methods for the diagnosis of chronic lower back and cervical pain
GB9508618D0 (en) * 1995-04-28 1995-06-14 Applied Research Systems Therapeutic protein
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
JP2004530417A (ja) * 2000-12-12 2004-10-07 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトキナーゼおよびそれをコードするポリヌクレオチド
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CN101253195A (zh) * 2005-08-26 2008-08-27 科莱尼斯医疗控股公司 用于在乳酸菌中制备载脂蛋白基因产物的组合物和方法
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
MY188457A (en) * 2008-10-03 2021-12-10 Opko Curna Llc Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
CA3033577A1 (en) 2008-11-10 2010-05-14 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010088537A2 (en) 2009-01-29 2010-08-05 Alnylam Pharmaceuticals, Inc. Improved lipid formulation
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2010129709A1 (en) 2009-05-05 2010-11-11 Alnylam Pharmaceuticals, Inc. Lipid compositions
EP2427553A4 (en) 2009-05-06 2012-11-07 Opko Curna Llc TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT
SMT201800499T1 (it) 2009-06-10 2018-11-09 Arbutus Biopharma Corp Formulazione lipidica migliorata
US9029338B2 (en) 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
IL300109A (en) 2010-06-03 2023-03-01 Alnylam Pharmaceuticals Inc Biodegradable lipids for the transfer of active substances
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
EP2663548B1 (en) 2011-01-11 2017-04-05 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP4400511A3 (en) 2011-02-07 2024-09-04 Abionyx Pharma SA Lipoprotein complexes and manufacturing and uses thereof
US9701623B2 (en) 2011-09-27 2017-07-11 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
KR20160002977A (ko) 2013-05-01 2016-01-08 아이시스 파마수티컬즈 인코포레이티드 조성물 및 방법
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
BR112016025470A2 (pt) 2014-05-02 2017-08-15 Cerenis Therapeutics Holding S A ?hdl terapêutico?
US11492616B2 (en) * 2016-10-27 2022-11-08 Institute Of Microbiology, Chinese Academy Of Sciences Method for modifying amino acid attenuator and use of same in production
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
KR20240018430A (ko) 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
AU2023251245A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
EP4536268A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
CN120857937A (zh) 2022-06-10 2025-10-28 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗急性病症的方法
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
AU6522486A (en) 1985-10-04 1987-04-24 Biotechnology Research Partners Limited Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
EP0269260A3 (en) * 1986-10-29 1988-06-22 Biotechnology Research Partners, Ltd. Apoai-ciii-aiv, apoaii apob, apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
FI100056B (fi) 1997-09-15
PL272698A1 (en) 1989-03-06
PT87562A (pt) 1989-05-31
CZ283648B6 (cs) 1998-05-13
HU204562B (en) 1992-01-28
FI882456L (fi) 1988-11-29
CZ363888A3 (cs) 1998-02-18
HK137794A (en) 1994-12-16
PL158064B1 (pl) 1992-07-31
DE3880739T2 (de) 1993-08-19
ES2054878T3 (es) 1994-08-16
CY1809A (en) 1995-10-20
DK289688A (da) 1988-11-29
FI882456A0 (fi) 1988-05-25
US5059528A (en) 1991-10-22
AU1672388A (en) 1988-12-01
PT87562B (pt) 1992-09-30
EP0293357B1 (fr) 1993-05-05
DE3880739D1 (de) 1993-06-09
KR970000808B1 (en) 1997-01-20
IL86480A0 (en) 1988-11-15
SU1834904A3 (ru) 1993-08-15
DD291093A5 (de) 1991-06-20
IE881597L (en) 1988-11-28
SG131594G (en) 1995-01-13
LT3600B (en) 1995-12-27
JPS6416589A (en) 1989-01-20
ZA883824B (en) 1989-02-22
EP0293357A1 (fr) 1988-11-30
LV5288A3 (lv) 1993-10-10
HUT47153A (en) 1989-01-30
SK279166B6 (sk) 1998-07-08
IL86480A (en) 1992-08-18
CN1031892C (zh) 1996-05-29
NO179253B (no) 1996-05-28
RU2009198C1 (ru) 1994-03-15
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
JP2634193B2 (ja) 1997-07-23
NO882341L (no) 1988-11-29
CA1323851C (en) 1993-11-02
DK175686B1 (da) 2005-01-17
ATE89006T1 (de) 1993-05-15
KR880014110A (ko) 1988-12-22
CN88103118A (zh) 1988-12-14
SK363888A3 (en) 1998-07-08
AU615654B2 (en) 1991-10-10
IE62422B1 (en) 1995-02-08
LTIP828A (en) 1995-02-27
UA19765A (uk) 1997-12-25
NO179253C (no) 1996-09-04
EG19101A (en) 1994-09-29
NZ224808A (en) 1990-01-29

Similar Documents

Publication Publication Date Title
NO882341L (no) Ekspresjon av humant proapolipoprotein a-i.
ES8705467A1 (es) Un procedimiento para producir la proteina apoacuorina
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
ES2059354T3 (es) Un metodo para producir un polipeptido.
NO940736L (no) DNA sekvenser som koder for gelonin polypeptid
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
NO930428L (no) Proteinstrukturen til plantetoksingelonin
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
DK595187D0 (da) Minactivin og fremgangsmaade til fremstilling deraf
DE69031996D1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
DE3856392D1 (de) Klonierung von Malaria-spezifischen DNA-Sequenzen:Isolierung des Gens für das 140 kd Protein
DE69636737D1 (de) Neues immunoregulatorisches protein lst-1

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees